Author | Robert B. Diasio, MD

Articles

Current Status of Oral Chemotherapy for Colorectal Cancer

March 02, 2001

The treatment of advanced colorectal cancer over the past 4 decades has required the use of intravenous chemotherapy, most typically fluorouracil (5-FU). The possibility of providing

Clinical Implications of Dihydropyrimidine Dehydrogenase on 5-FU Pharmacology

January 02, 2001

Dihydropyrimidine dehydrogenase (DPD) is the initial rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), accounting for catabolism of over 85% of an administered dose of 5-FU. DPD plays an important role in

Oral DPD-Inhibitory Fluoropyrimidine Drugs

October 01, 2000

Over the past decade, increasing data have emphasized both the importance of dihydropyrimidine dehydrogenase (DPD), the initial, rate-limiting enzyme in the catabolism of fluorouracil (5-FU), and its role as a control step in 5-FU metabolism, regulating the availability of 5-FU for anabolism.

The Role of Dihydropyrimidine Dehydrogenase (DPD) Modulation in 5-FU Pharmacology

October 01, 1998

Over the past several years, the pyrimidine catabolic pathway and, in particular, the first enzymatic step involving dihydropyrimidine dehydrogenase (DPD) have been recognized as being critical in determining the ultimate